Nipocalimab Reduces Sjögren’s Disease Activity in Ph...

The Phase 2 DAHLIAS study (NCT04968912), a multicenter, randomized, placebo-controlled, double-blind trial, evaluated nipocalimab—an investigational monoclonal antibody targeting the neonatal Fc rec...

Published: 27 Oct 2025

Written by Pooja Vasala